Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103152 | 0.83 | LMNA (0.68) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL16301357 | 0.83 | LMNA (0.68) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL28824364 | 0.83 | LMNA (0.68) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL6201445 | 0.81 | LMNA (0.64) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL27209667 | 0.80 | GAA (0.46) | LMNATDP1TRPV6ALDH1A1SMN1; SMN2 | |
| SCHEMBL22910536 | 0.80 | LMNA (0.62) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL10544332 | 0.80 | LMNA (0.62) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL10549969 | 0.80 | LMNA (0.62) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL10223959 | 0.80 | LMNA (0.62) | LMNATDP1TRPV6CYP19A1ALDH1A1 | |
| SCHEMBL358425 | 0.78 | LTA4H (0.67) | TDP1ALDH1A1SMN1; SMN2HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | LMNA 4846/4885TDP1 3492/4885TRPV6 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.